CD8 T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4 T Cells <200 Cell/μL: The DART Trial STI Substudy. by Serwanga, J, Mugaba, S, Betty, A, Pimego, E, Walker, A, Munderi, P, Gilks, C, Gotch, F, Grosskurth, H, Kaleebu, P

Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy. by Kikaire, B, Khoo, S, Walker, A, Ssali, F, Munderi, P, Namale, L, Reid, A, Gibb, D, Mugyenyi, P, Grosskurth, H

Patterns of sexual behaviour in a rural population in north-western Tanzania. by Munguti, K, Grosskurth, H, Newell, J, Senkoro, K, Mosha, F, Todd, J, Mayaud, P, Gavyole, A, Quigley, M, Hayes, R

The impact of different CD4 cell-count monitoring and switching strategies on mortality in HIV-infected African adults on antiretroviral therapy: an application of dynamic marginal... by Ford, D, Robins, JM, Petersen, ML, Gibb, DM, Gilks, CF, Mugyenyi, P, Grosskurth, H, Hakim, J, Katabira, E, Babiker, A, Walker, A

Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa. by Stöhr, W, Reid, A, Walker, A, Ssali, F, Munderi, P, Mambule, I, Kityo, C, Grosskurth, H, Gilks, C, Gibb, D, Hakim, J

Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine... by Munderi, P, Walker, A, Kityo, C, Babiker, A, Ssali, F, Reid, A, Darbyshire, J, Grosskurth, H, Mugyenyi, P, Gibb, D, Gilks, C

The Impact of Different CD4 Cell-Count Monitoring and Switching Strategies on Mortality in HIV-Infected African Adults on Antiretroviral Therapy: An Application of Dynamic Marginal... by Ford, D, Robins, J, Petersen, M, Gibb, D, Gilks, C, Mugyenyi, P, Grosskurth, H, Hakim, J, Katabira, E, Babiker, A, Walker, A

A single CD4 test with 250 cells/mm3 threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteria by Gilks, C, Walker, A, Munderi, P, Kityo, C, Reid, A, Katabira, E, Goodall, R, Grosskurth, H, Mugyenyi, P, Hakim, J, Gibb, D

Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. by Mugyenyi, P, Walker, A, Hakim, J, Munderi, P, Gibb, D, Kityo, C, Reid, A, Grosskurth, H, Darbyshire, J, Ssali, F, Bray, D, Katabira, E, Babiker, A, Gilks, C, Grosskurth, H, Munderi, P, Kabuye, G, Nsibambi, D, Kasirye, R, Zalwango, E, Nakazibwe, M, Kikaire, B, Nassuna, G, Massa, R, Fadhiru, K

P04-11. Prevalence of neutralizing antibody responses in chronic clades A and D human immunodeficiency virus type 1 (HIV-1) infections by Grosskurth H, Kamali A, Maher D, Levin J, Vanham G, Balla S, Montefiori D, Sokolik-Wolak B, Tomusange K, Njai HF, Pala P, Kaleebu P

Antibody to herpes simplex virus type 2 as a marker of sexual risk behavior in rural Tanzania. by Obasi, A, Mosha, F, Quigley, M, Sekirassa, Z, Gibbs, T, Munguti, K, Todd, J, Grosskurth, H, Mayaud, P, Changalucha, J, Brown, D, Mabey, D, Hayes, R

Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART coh... by Walker, A, Ford, D, Gilks, C, Munderi, P, Ssali, F, Reid, A, Katabira, E, Grosskurth, H, Mugyenyi, P, Hakim, J, Darbyshire, J, Gibb, D, Babiker, A

Higher risk behaviour and rates of sexually transmitted diseases in Mwanza compared to Uganda may help explain HIV prevention trial outcomes. by Orroth, K, Korenromp, E, White, R, Gavyole, A, Gray, R, Muhangi, L, Sewankambo, N, Quigley, M, Wawer, M, Whitworth, J, Grosskurth, H, Habbema, J, Hayes, R

Sexual behaviour patterns and other risk factors for HIV infection in rural Tanzania: a case-control study. by Quigley, M, Munguti, K, Grosskurth, H, Todd, J, Mosha, F, Senkoro, K, Newell, J, Mayaud, P, ka-Gina, G, Klokke, A, Mabey, D, Gavyole, A, Hayes, R

Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. by Ssali, F, Stöhr, W, Munderi, P, Reid, A, Walker, A, Gibb, D, Mugyenyi, P, Kityo, C, Grosskurth, H, Hakim, J, Byakwaga, H, Katabira, E, Darbyshire, J, Gilks, C

Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. by Gibb, D, Kizito, H, Russell, E, Chidziva, E, Zalwango, E, Nalumenya, R, Spyer, M, Tumukunde, D, Nathoo, K, Munderi, P, Kyomugisha, H, Hakim, J, Grosskurth, H, Gilks, C, Walker, A, Musoke, P

Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretro... by Ross, LL, Walker, AS, Lou, Y, Tenorio, AR, Gibb, DM, Double, J, Gilks, C, McCoig, CC, Munderi, P, Musoro, G, Kityo, CM, Grosskurth, H, Hakim, J, Mugyenyi, PN, Cutrell, A, Perger, T, Shaefer, MS

Cost Effectiveness Analysis of Clinically Driven versus Routine Laboratory Monitoring of Antiretroviral Therapy in Uganda and Zimbabwe by Lara, A, Kigozi, J, Amurwon, J, Muchabaiwa, L, Wakaholi, B, Mota, R, Walker, A, Kasirye, R, Ssali, F, Reid, A, Grosskurth, H, Babiker, A, Kityo, C, Katabira, E, Munderi, P, Mugyenyi, P, Hakim, J, Darbyshire, J, Gibb, D, Gilks, C, DARTT Team